Matrixyl

Matrixyl is a synthetic lipopeptide: the pentapeptide KTTKS (Lys-Thr-Thr-Lys-Ser) — a fragment naturally released from the C-terminal propeptide of type I procollagen — conjugated to palmitic acid to improve lipophilicity and penetration across the stratum corneum. KTTKS acts as a matrikine, a peptide 'feedback' signal that the skin interprets as evidence of matrix turnover, cueing dermal fibroblasts to up-regulate synthesis of type I and III collagen, fibronectin and glycosaminoglycans. The palmitoyl tail is a delivery modification and is not itself bioactive. Because it is applied topically at very low concentrations (parts per million) as a cosmetic active, its action is confined to the skin surface and upper dermis; it is not designed for, or studied as, a systemic drug.

Matrixyl is a cosmetic ingredient, not a medicine. The matrikine mechanism was established in cell culture by Katayama et al. (1993), who mapped KTTKS as the minimal procollagen sequence that stimulates matrix production in fibroblasts. The most cited human data is Robinson et al. (2005): a 12-week double-blind, split-face, placebo-controlled trial in 93 women reporting statistically significant reductions in wrinkle depth and skin roughness on the pal-KTTKS side versus vehicle. Effect sizes are modest, trials are small and largely industry-associated, and results describe cosmetic appearance rather than a therapeutic outcome.

Educational overview only — no dosing instructions in the public hub.

Generally well tolerated in topical cosmetic use; reported effects are gradual and cosmetic rather than clinical. The main practical concerns are formulation-side: peptide stability, actual delivered concentration, and irritation or sensitisation from other ingredients in a finished product rather than from pal-KTTKS itself. It is not intended for injection or systemic use, and no such use has been studied. Marketing claims frequently overstate the modest, appearance-level evidence.

Confirm the INCI name (Palmitoyl Pentapeptide-4) and request a supplier CoA documenting identity and purity; finished cosmetics should disclose the peptide concentration, as efficacy studies use only parts-per-million levels. Because it is a small peptide prone to degradation, formulation pH, packaging and storage materially affect whether any active remains at point of use.

Regulated as a permitted cosmetic ingredient (INCI: Palmitoyl Pentapeptide-4) in the EU, UK and US. It is a cosmetic active, not an approved therapeutic drug, and may not be marketed with medical or drug claims.